1. Home
  2. Companies
  3. NUZ
  4. Material Events

Neurizon Therapeutics (ASX:NUZ) — Material Events

ASX:NUZ · 28 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 3 articles Significant 19 articles Notable 6 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
19
Neurizon Raises A$24.2m to Propel ALS Drug NUZ-001 into Pivotal TrialHigh
Neurizon launches A$24.2m equity raise to fund ALS trial and commercialisation of NUZ-001
23 Dec 2025 ·Equity Raising Presentation ·85
Neurizon Launches Pivotal Phase 2/3 Trial of NUZ-001 in ALS PatientsMedium
Neurizon Begins Phase 2/3 Dosing of NUZ-001 in HEALEY ALS Platform Trial
26 Feb 2026 ·Clinical Trial Update ·85
Neurizon Secures $44M to Propel NUZ-001 in Pivotal ALS TrialHigh
Neurizon secures $44.2M funding package to advance NUZ-001 in HEALEY ALS Platform Trial
23 Dec 2025 ·Capital Raising ·85
Neurizon Clears FDA Hold, Raises $5.2M, Advances ALS Drug NUZ-001Medium
Neurizon clears FDA clinical hold, raises $5.2M, advances NUZ-001 into HEALEY ALS trial
31 Oct 2025 ·Shareholder Update Webinar Announcement ·85
FDA Clears Neurizon’s NUZ-001 for Pivotal ALS Trial in Late 2025High
FDA lifts clinical hold on Neurizon's NUZ-001, clearing path for ALS platform trial in late 2025
6 Oct 2025 ·Regulatory Update ·85
Neurizon Advances ALS Drug with Key GMP Manufacturing MilestoneMedium
Neurizon completes GMP batches of NUZ-001, advancing FDA submission and ALS trial enrollment
4 Dec 2025 ·Regulatory Update ·85
Neurizon Advances ALS Therapy with FDA Clinical Hold Response SubmittedMedium
Neurizon submits FDA clinical hold response for NUZ-001, targets ALS trial in Q4 2025
25 July 2025 ·Regulatory Update ·85
Neurizon Advances NUZ-001 with New Formulation and FDA MilestonesHigh
Neurizon advances NUZ-001 development with new formulation, positive clinical data, FDA engagement, and Elanco licensing deal
30 July 2025 ·Quarterly Report & Appendix 4C ·85
Neurizon Therapeutics Doubles Loss as NUZ-001 Advances Toward ALS TrialHigh
Neurizon Therapeutics reports $16.6M loss, advances NUZ-001 ALS therapy with key regulatory and licensing milestones
26 Aug 2025 ·Annual Report and Appendix 4E ·85
FDA Clears Neurizon’s NUZ-001 for Pivotal ALS Platform Trial EntryMedium
Neurizon's NUZ-001 Cleared by FDA for HEALEY ALS Platform Trial Entry
11 Dec 2025 ·Regulatory Update ·85
Neurizon Locks in Five-Year Supply Deal with Elanco to Boost NUZ-001 CommercialisationMedium
Neurizon secures five-year supply agreement with Elanco to advance NUZ-001 commercialisation
17 June 2026 ·Supply Agreement Announcement ·80
Neurizon Secures $5M to Propel ALS Drug into Pivotal TrialMedium
Neurizon Raises $5M via Institutional Placement to Advance ALS Drug Development
18 Sept 2025 ·Capital Raising ·80
Neurizon Expands HEALEY ALS Trial Cohort to 240 Participants with Accelerated Timeline and Stable CostsMedium
Neurizon expands HEALEY ALS trial cohort to 240 participants with accelerated timeline and stable costs
27 May 2026 ·Clinical Trial Update ·80
Neurizon Passes Halfway Mark in Expanded HEALEY ALS Trial Ahead of ScheduleMedium
Neurizon surpasses 50% dosing milestone in HEALEY ALS Platform Trial ahead of schedule
12 June 2026 ·Clinical Trial Progress Update ·75
Neurizon Advances ALS Drug Trial Despite FDA Fast Track SetbackMedium
Neurizon's ALS Drug NUZ-001 Advances in Clinical Trial; FDA Denies Fast Track Designation Pending More Data
2 Jan 2026 ·Regulatory and Development Update ·75
Neurizon Secures $5.88M to Propel ALS Drug Trial ForwardMedium
Neurizon raises $5.88M via entitlement offer to fund ALS trial progress
27 Jan 2026 ·Capital Raising ·75
Neurizon Secures $5.6M R&D Tax Incentive Boost for NUZ-001 ALS ProgramMedium
Neurizon Secures AUD 5.6M R&D Tax Incentive Advance for NUZ-001 Development
18 Sept 2025 ·ASX Announcement ·75
Neurizon Raises A$2.7M to Close Entitlement Offer Shortfall, Boosting NUZ-001 DevelopmentMedium
Neurizon raises A$2.7M via placement of entitlement offer shortfall to support NUZ-001 development
16 Apr 2026 ·Capital Raising ·75
Neurizon Secures Long-Term Australian Patent for NUZ-001 in Neurodegenerative DiseasesMedium
Neurizon secures Australian patent for NUZ-001, advancing neurodegenerative disease treatment pipeline
21 Oct 2025 ·Patent Grant Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.